Mannkind Corporation
CompanyUnited StatesFounded 1991
Mannkind Corporation develops 2 assets, the furthest in phase 3 (insulin in asthma). Mostly protein or enzyme acting on Insulin/IGF-1 signalling, glycolysis and INSR; based in the United States, founded in 1991.
- 2
- Assets
- Furthest stage
- Phase 3
- 6
- Trials
- 0
- Signals
Pipeline
2Activates insulin receptors to support retinal neuron survival and neuroprotection.
Phase 3, Protein or enzyme, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, asthma, chronic obstructive pulmonary disease
Inhaled rapid-acting human insulin formulation that activates the insulin receptor.
Phase 2, Protein or enzyme, Insulin/IGF-1 signalling, Glycolysis, type 2 diabetes, chronic obstructive pulmonary disease (Phase 1)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials7
- Signals1
- Similar companies6